HRS Post 2026

1. Which statement best captures the biologic rationale for targeting FXI/XIa in stroke prevention in AF rather than simply intensifying factor Xa inhibition?

2. Which pairing correctly contrasts a zymogen-level monoclonal antibody strategy with an oral small-molecule FXIa inhibitor?

3. Which trial-population-control pairing is correct?

4. Why does OCEANIC-AF remain important when interpreting ongoing Phase 3 FXI/XIa inhibitor programs in AF?

5. If a FXIa inhibitor were to demonstrate noninferior efficacy versus apixaban with less clinically relevant bleeding, which change would be most plausible first in electrophysiology practice?

6. In an EP clinic, which patient phenotype is most directly aligned with the clinical question being tested in LILAC-TIMI 76?

Name

First NameLast Name

Degree(s)

Email

example@example.com

Which of the following best describes your title?

***If PharmD, please provide NABP ID#:

***If PharmD, please provide DOB:

Date

How many years have you been in practice?

How many patients with atrial fibrillation do you typically see each month?

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Describe the biologic and mechanistic rationale for targeting factor XI/XIa in SPAF, and contrast FXI/XIa directed strategies with current factor Xa based DOAC therapy
Differentiate mechanistic approaches to FXI pathway modulation—including zymogenlevel inhibition with a monoclonal antibody and activesite inhibition with oral smallmolecule FXIa inhibitors—and discuss how these differences may translate into distinct clinical profiles
Evaluate the design, populations, and key endpoints of LIBREXIAAF and LILACTIMI 76 in the context of prior FXI/XIa inhibitor trials (including OCEANICAF) to assess how these ongoing Phase 3 programs test the FXI/XIa hypothesis in AF
Evaluate the design, populations, and key endpoints of LIBREXIAAF and LILACTIMI 76 in the context of prior FXI/XIa inhibitor trials (including OCEANICAF) to assess how these ongoing Phase 3 programs test the FXI/XIa hypothesis in AF

Do you feel this activity was fair balanced and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

This educational activity will result in a change in my practice behavior.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

Course Title

Date

Credits

Attestation to time spent on activity:

AcademicCME designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™, 1.25 CNE Contact Hours (Provider #P0491) or 1.25 CPE Contact Hours for participation in the full educational activity.

Please select your credit type from the below:

AcademicCME thanks you for your participation in this activity.
All information provided improves the scope and purpose of our programs.